Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Vertex Pharmaceuticals: Balancing Growth Prospects and Uncertainties with a Hold Rating
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...
ORG Partners LLC Has $41,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...
International Assets Investment Management LLC Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
My 3 Highest-Conviction Growth Stocks to Buy in 2025
However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
clinicaladvisor.com12d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Investing27d
Vertex Pharmaceuticals' SWOT analysis: biotech stock poised for growth beyond CF
Vertex Pharmaceuticals (NASDAQ ... primarily known for its groundbreaking cystic fibrosis (CF) treatments. The company generated impressive revenues of $10.6 billion in the last twelve months ...